Incyte to Present at Upcoming Investor Conferences

10/30/24 8:00:00 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $INCY alert in real time by email

Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November:

Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST)
Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030557532/en/

Get the next $INCY alert in real time by email

Date	Price Target	Rating	Analyst
10/29/2024	$68.00 → $90.00	Neutral → Buy	BofA Securities
10/1/2024	$84.00	Outperform	Wolfe Research
9/18/2024	$83.00 → $74.00	Buy → Hold	Truist
7/2/2024	$52.00 → $48.00	Market Perform → Underperform	BMO Capital Markets
5/23/2024	$55.00	Hold	Deutsche Bank
4/23/2024		Neutral	Cantor Fitzgerald
2/23/2024	$81.00	Buy	Jefferies
2/14/2024		Mkt Outperform → Mkt Perform	JMP Securities

Incyte to Present at Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $INCY

$INCY Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Incyte Corp.

Amendment: SEC Form SC 13D/A filed by Incyte Corp.

SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

$INCY SEC Filings

SEC Form 10-Q filed by Incyte Corp.

Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Incyte Corp.

$INCY Press Releases

Fastest customizable press release news feed in the world

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte to Present at Upcoming Investor Conference

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$INCY Leadership Updates

Live Leadership Updates

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

Incyte Names New Member to Its Board of Directors

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

$INCY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Incyte upgraded by BofA Securities with a new price target

Wolfe Research initiated coverage on Incyte with a new price target

Incyte downgraded by Truist with a new price target

$INCY Market Insights

Live Market Insights

S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?

This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Incyte shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and lowered its price target from $52 to $48.

$INCY Financials

Live finance-specific insights

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte to Report Third Quarter Financial Results

Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

$INCY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP & General Manager US Flannelly Barry P exercised 3,680 shares at a strike of $70.03 and sold $293,210 worth of shares (3,680 units at $79.68) (SEC Form 4)

EVP & General Counsel Denton Sheila A. covered exercise/tax liability with 2,136 shares, decreasing direct ownership by 7% to 30,343 units (SEC Form 4)

EVP, Head of Incyte Intl Heeson Lee was granted 26,447 shares (SEC Form 4)

$INCY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for JAKAFI issued to INCYTE CORP

FDA Approval for OPZELURA issued to INCYTE CORP

Recent Analyst Ratings for
$INCY

$INCY
Large Ownership Changes

$INCY
SEC Filings

$INCY
Press Releases

$INCY
Leadership Updates

$INCY
Analyst Ratings

$INCY
Market Insights

$INCY
Financials

$INCY
Insider Trading

$INCY
FDA approvals